
Human stem-cell derived cardiomyocyte MEA assays can screen for pro-arrhythmic effects. These models enable real-time monitoring of functional electrophysiological endpoints that parallel clinical safety markers.
The inability to predict the cardiovascular liability of therapeutic compounds prior to clinical trials has resulted in numerous costly late-stage drug development failures and market withdrawals leading to the development of New Approach Methodologies (NAMs).
Providing deep insights into human in vitro models, the Maestro MEA platform is a vital tool for any cardiac safety testing paradigm.
Translatable human in vitro cardiac assay
MEA technology is a powerful tool for predicting cardiac risk.
Analogous to an in vivo EKG signal, an MEA field potential can measure changes in beating, depolarization and repolarization. But the Maestro MEA platform is more than MEA:
- Arrhythmia detection
Maestro MEA is the only MEA platform capable of LEAP™ action potential analysis. - Propagation alterations
Propagation issues can lead to deadly re-entrant currents. MEA is the best platform for evaluating propagation changes in vitro. - Contractility assessment
Measuring both electrical and contractile properties across the culture. - Viability multiplexing
Maestro MEA can simultaneously measure viability and function.

Real-time, label-free in vitro cardiac analysis
-
Highly reproducible and predictive in vitro cardiotoxicity assay>
-
Measure real-time, label-free in vitro cardiac activity>
-
Detect subtle changes in action potential morphology>
-
Assay steps: Human iPSC-derived cardiomyocytes>
-
Establishing a functional standard for stem-derived cardiomyocytes>
-
Application Note: Development of a functional cardiotoxicity assay for evaluating the safety of cell therapies>
-
Track propagation across the cardiac syncytium>
-
Elicit mature force-frequency responses with chronic pacing>
The Maestro MEA cardiac activity assay has been proven to be highly accurate with low variability. In a multi-site, blinded study to assess proarrhythmic risk of cardioactive compounds, Maestro MEA outperformed the competition in a head-to-head comparison.
| Maestro MEA | MEA2100 | xCELLigence RTCA CardioECR |
Most Reliable Sites that passed QC | 85% | 42% | 25% |
Most Accurate Identified compounds expected to induce a 20% change in FPDc | 93% | 50% | 75% |
Lowest Variability Well-to-well FPDc variability in baseline | 6.4% | 21.5% | 15.2% |
The study (Millard et al, 2018) investigated 8 compounds in 18 studies across 13 global sites, 3 MEA platforms, and 4 hiPSC cardiomyocyte sources. 85% of Maestro MEA sites passed initial QC, more than double the next MEA system.

Of the 10 studies that passed QC acceptance criteria, Maestro MEA had the lowest well-to-well variability, 58% less than the next lowest despite being performed across 6X as many sites.
The Maestro MEA assay correctly identified test compounds 93% of the time. A follow-up study (Blinova et al 2018) expanded the scope to 28 blinded compounds of low, intermediate, and high risk. Maestro MEA had a 0.93 correlation coefficient between study sites.
With these studies, together with key opinion leaders in academia and industry, Axion has developed a proposed standard for hiPSC cardiomyocytes.

Cardiac Metric Definitions
Discover our Cardiac Metrics Definition guide to discover the full list of metrics available in our cardiac analysis tool.